Universe Pharmaceuticals Q4 2025 Earnings Report

Universe Pharmaceuticals EPS Results

• Actual EPS: $0.69
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Universe Pharmaceuticals Revenue Results

• Actual Revenue: $8.92 billion
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Universe Pharmaceuticals Announcement Details

• Quarter: Q4 2025
• Date: 1/29/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Universe Pharmaceuticals (NASDAQ:UPC), Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action. In parallel, Universe is exploring additional pipeline assets aimed at reducing post-operative scarring and controlling inflammation in anterior segment surgeries. Preclinical studies have demonstrated favorable pharmacokinetics and tissue penetration in animal models, supporting the potential for once-daily dosing regimens.

Headquartered in the United Kingdom with a research subsidiary in the United States, Universe Pharmaceuticals maintains collaborations with academic institutions and contract development organizations to accelerate its drug development programs. The company is led by a management team with extensive experience in ophthalmology drug development and regulatory strategy, positioning it to advance its candidates through late-stage clinical trials and toward commercialization.